Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code AGR

16. Specific lobbying issues

Biomass Programs (Non-Funding)
---Farm Bill Reauthorization
---Reauthorization of Biomass Crop Assistance Program
---Reauthorization of Biomass R&D Program

EPA Regulations on Biotechnology
---Efficient Science-Based Review of Biotech Products
---H.R. 1029: Pesticide Registration Improvement Extension Act of 2017

Foreign Agricultural Biotechnology Laws and Regulations
---Asynchronous Approvals
---China Biotechnology Regulations
---EU Ag-Biotech Policies and Regulations

Funding for Biomass Crop Assistance Program
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Farm Bill Reauthorization

Funding for the USDA
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018

Genetically Engineered (GE) Animals
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Amendment on GE Salmon Labeling
---Efficient Science-Based Review of Biotech Products
---FDA Proposed Guidance on Gene Editing
---Labeling
---The One Health Act (Sen. Franken Discussion Draft)

North American Free Trade Agreement (NAFTA) Renegotiation
---Ag-Biotech Provisions

One Health
---The One Health Act (Sen. Franken Discussion Draft)

Potential Regulation of New Genetic Modification Technologies

Review and Labeling of Food Derived From Biotechnology
---Implementation of Disclosure Law

Review of the Federal Coordinated Framework for Biotechnology Products

USDA/APHIS Agricultural Biotechnology Regulations
---Efficient Science-Based Review of Biotech Products
---Farm Bill Reauthorization
---Potential Revisions to Part 340 Regulations

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Commerce - Dept of (DOC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), Natl Economic Council (NEC), Natl Security Council (NSC), U.S. Trade Representative (USTR), White House Office, Office of Management & Budget (OMB), Agriculture - Dept of (USDA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ANI

16. Specific lobbying issues

Genetically Engineered (GE) Animals
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Amendment on GE Salmon Labeling
---Efficient Science-Based Review of Biotech Products
---FDA Proposed Guidance on Gene Editing
---Labeling
---The One Health Act (Sen. Franken Discussion Draft)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), White House Office, Office of Management & Budget (OMB), Natl Economic Council (NEC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

Energy Basic Research Funding
---Advanced Research Projects Agency - Energy
---DOE Office of Science
---Energy and Water Development and Related Agencies Appropriations Act for FY 2018

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---Department of Defense Appropriations Act for FY 2018
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018

Funding for Biofuels
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Department of Defense Appropriations Act for FY 2018
---Department of Defense Funding of Advanced Biofuels
---Energy and Water Development and Related Agencies Appropriations Act for FY 2018
---Farm Bill Reauthorization

Funding for Biomass Crop Assistance Program
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Farm Bill Reauthorization

Funding for Biorefineries
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018

Farm Bill Reauthorization
---H.R.2810: National Defense Authorization Act for 2018
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program

Funding for Antimicrobial Resistance Programs
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018

Funding for FDA
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018

Funding for National Institutes of Health
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018

Funding for Renewable Chemicals/Bio-based Products
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---EPA Safer Choice Program
---Farm Bill Reauthorization
---H.R.2810: National Defense Authorization Act for 2018
---Reauthorization of USDA Bio-Preferred Program
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance ---Program

Funding for the Centers for Disease Control and Prevention Vaccine Programs
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018

Funding for the USDA
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CHM

16. Specific lobbying issues

Funding for Renewable Chemicals/Bio-based Products
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---EPA Safer Choice Program
---Farm Bill Reauthorization
---H.R.2810: National Defense Authorization Act for 2018
---Reauthorization of USDA Bio-Preferred Program
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program

Renewable Chemicals/Bio-based Products (Non-Funding)
---Expansion of Master Limited Partnerships to Renewable Chemicals
---Farm Bill Reauthorization
---HR 3149: Renewable Chemicals Act of 2017
---Investment Tax Credit
---Production Tax Credit
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program
---Reauthorization of USDA Bio-Preferred Program

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

Intellectual Property International Enforcement
---Compulsory Licensing
---India

Inter Partes Review
---Implementation of the America Invents Act of 2011
--S. 1390: STRONGER Patents Act

Patent Reform
---Patent Litigation Reforms
---S. 1390: STRONGER Patents Act

Patenting of Biological Inventions
---Argentina Biotech Patentability Guidelines
---Section 101 Modernization

UN High Level Commission on Access to Medicines
---IP Proposals

World Health Organization Cancer Resolution
---Pricing and IP Language

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Patent & Trademark Office (PTO)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CSP

16. Specific lobbying issues

Drug Importation
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---S. 771: Improving Access to Affordable Prescription Drugs
---S.469: Affordable and Safe Prescription Drug Importation Act
---Welch Amendment to: H.R. 2430: FDA Reauthorization Act of 2017
---S.934/H.R.2430: FDA Reauthorization Act of 2017

Genetically Engineered (GE) Animals
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Amendment on GE Salmon Labeling
---Efficient Science-Based Review of Biotech Products
---FDA Proposed Guidance on Gene Editing
---Labeling
---The One Health Act (Sen. Franken Discussion Draft)

Review and Labeling of Food Derived From Biotechnology
---Implementation of Disclosure Law

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Environmental Protection Agency (EPA), Natl Economic Council (NEC), Office of Management & Budget (OMB), White House Office, Agriculture - Dept of (USDA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ENG

16. Specific lobbying issues

Biofuels (Non-Funding)
---Accelerated Depreciation of Biofuels Facilities Extension
---Farm Bill Reauthorization
---Production Tax Credit Extension
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance ---Program

Biomass Programs (Non-Funding)
---Farm Bill Reauthorization
---Reauthorization of Biomass Crop Assistance Program
---Reauthorization of Biomass R&D Program

Energy Basic Research Funding
---Advanced Research Projects Agency - Energy
---DOE Office of Science
---Energy and Water Development and Related Agencies Appropriations Act for FY 2018

Funding for Biofuels
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Department of Defense Appropriations Act for FY 2018
---Department of Defense Funding of Advanced Biofuels
---Energy and Water Development and Related Agencies Appropriations Act for FY 2018
---Farm Bill Reauthorization

Funding for Biomass Crop Assistance Program
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Farm Bill Reauthorization

Funding for Biorefineries
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Farm Bill Reauthorization
---H.R.2810: National Defense Authorization Act for 2018
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program

Renewable Fuel Standard
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Changes to the Point of Obligation under the RFS
---H.R. 1311/S.517: Consumer and Fuel Retailer Choice Act
---RFS Reform
---Proposed Rule for 2018 Volumes

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Environmental Protection Agency (EPA), Office of Management & Budget (OMB), Natl Economic Council (NEC), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code FOO

16. Specific lobbying issues

Genetically Engineered (GE) Animals
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Amendment on GE Salmon Labeling
---Efficient Science-Based Review of Biotech Products
---FDA Proposed Guidance on Gene Editing
---Labeling
---The One Health Act (Sen. Franken Discussion Draft)

Review and Labeling of Food Derived From Biotechnology
---Implementation of Disclosure Law

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), Office of Management & Budget (OMB), Natl Economic Council (NEC), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code FUE

16. Specific lobbying issues

Biofuels (Non-Funding)
---Accelerated Depreciation of Biofuels Facilities Extension
---Farm Bill Reauthorization
---Production Tax Credit Extension
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance ---Program

Biomass Programs (Non-Funding)
---Farm Bill Reauthorization
---Reauthorization of Biomass Crop Assistance Program
---Reauthorization of Biomass R&D Program

Energy Basic Research Funding
---Advanced Research Projects Agency - Energy
---DOE Office of Science
---Energy and Water Development and Related Agencies Appropriations Act for FY 2018

Funding for Biofuels
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Department of Defense Appropriations Act for FY 2018
---Department of Defense Funding of Advanced Biofuels
---Energy and Water Development and Related Agencies Appropriations Act for FY 2018
---Farm Bill Reauthorization

Funding for Biomass Crop Assistance Program
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Farm Bill Reauthorization

Funding for Biorefineries
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Farm Bill Reauthorization
---H.R.2810: National Defense Authorization Act for 2018
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program

Renewable Fuel Standard
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Changes to the Point of Obligation under the RFS
---H.R. 1311/S.517: Consumer and Fuel Retailer Choice Act
---RFS Reform
---Proposed Rule for 2018 Volumes

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Environmental Protection Agency (EPA), Natl Economic Council (NEC), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

340B Drug Discount Program
---340B Program Reforms (Rep. C. Collins Discussion Draft)
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---Program Implementation & Oversight

Affordable Care Act - Repeal and Replace
---H.R. 1628: American Health Care Act
---The Better Care Reconciliation Act of 2017 (Senate Discussion Drafts)

Antibiotic & Diagnostic Tax Credit
---H.R. 1840: Reinvigorating Antibiotic and Diagnostic Innovation Act of 2017

Biodefense Research, Development, and Procurement Issues (Nonfunding)
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---Implementation of Medical Countermeasures Innovation Act
---Tropical Disease Priority Review Voucher (PRV) Program
---S.934/H.R. 2430: FDA Reauthorization Act of 2017

Biosimilars
---Access to Samples for Testing
---Biosimilar User Fee Act Reauthorization and Implementation
---Brazil Biologics Regulations
---Coding
---India Biologics Regulations
---Interchangeability and Pharmacy Substitution
---Mexico Biologics Regulations
---Naming
---Patent Certification
---S. 974/H.R. 2212: CREATES Act of 2017
---S.934/H.R. 2430: FDA Reauthorization Act of 2017

Drug Evaluation and Review
---Compassionate Use/Expanded Access
---Expedited Pathways
---FDA Hiring Flexibility
---FDA Management and Financial Accountability
---FDA Proposed Rule on Changes to Drug Labeling
---Government Hiring Freeze
---Innovation Incentives
---Patient-Focused Drug Development
---Priority Review Voucher Programs
---Regulatory Reform & Modernization
---Reauthorization of the Prescription Drug User Fee Act
---Special Medical Use/Limited Population Drug
---Use of Real-World Evidence
---S.204 -H.R. 878: Rights to Try Act of 2017
---S.456 - H.R. 1231: RACE for Children Act
---S.934/H.R. 2430: FDA Reauthorization Act of 2017

Drug Importation
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---S. 771: Improving Access to Affordable Prescription Drugs
---S.469: Affordable and Safe Prescription Drug Importation Act
---Welch Amendment to: H.R. 2430: FDA Reauthorization Act of 2017
---S.934/H.R. 2430: FDA Reauthorization Act of 2017

Drug Manufacturing, Quality & Distribution
---Counterfeiting
---Drug Shortages
---Pharmacy Compounding & Oversight
---Supply Chain Integrity and Traceability

Drug Pricing
---S. 771: Improving Access to Affordable Prescription Drugs
---S. 1348: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2017
---S.934/H.R. 2430: FDA Reauthorization Act of 2017

Drug Product Communications
---The Medical Products Communications Act of 2017 (Rep. Griffith Discussion Draft)
---S.934/H.R. 2430: FDA Reauthorization Act of 2017

Funding for Antimicrobial Resistance Programs
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---Department of Defense Appropriations Act for FY 2018
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018

Funding for FDA
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018

Funding for National Institutes of Health
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018

Funding for the Centers for Disease Control and Prevention Vaccine Programs
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018

Generic Drug Entry
---Access to Samples for Testing
---Generic Drug Application Review Reforms
---Incentives for Generic Entry
---H.R. 297: Increasing Competition in Pharmaceuticals Act
---H.R. 749: Lower Drug Costs through Competition Act
---S. 974/H.R. 2212: CREATES Act of 2017
---S.934/H.R. 2430: FDA Reauthorization Act of 2017

Medicaid
---Average Manufacturer Price Calculations
---Drug Benefit Design
---Pricing and Rebates

North American Free Trade Agreement (NAFTA) Renegotiation
---Pricing and Reimbursement Provisions
---Regulatory Harmonization
---IP Provisions

Orphan Drug Issues
---RACE for Children Act (Discussion Draft)
---Tax Credit
---Technical Amendments
---S.934/H.R. 2430: FDA Reauthorization Act of 2017

Reimbursement for Innovative Products
---Medicare Part B Physician-Administered Products
---Medicare Part D Prescription Drug Program
---S. 771: Improving Access to Affordable Prescription Drugs
---Third Party Support of Patient Premiums and Cost-Sharing Obligations
---Value-based Contracting and Communications

UN High Level Commission on Access to Medicines
---IP Proposals

Vaccines and Infectious Diseases
---H.R. 1628: American Health Care Act
---Vaccine and Anti-Microbial Resistance Product Development and Incentives
---Vaccine Injury Compensation Program
---Vaccine Safety

Foreign Drug Data Protection Laws
---Israel

Trade and Foreign Drug Price Controls

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), Treasury - Dept of, U.S. Trade Representative (USTR), Natl Economic Council (NEC), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HOM

16. Specific lobbying issues

Biodefense Research, Development, and Procurement Issues (Nonfunding)
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---Implementation of Medical Countermeasures Innovation Act
---Tropical Disease Priority Review Voucher (PRV) Program
---S.934/H.R. 2430: FDA Reauthorization Act of 2017

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---Department of Defense Appropriations Act for FY 2018
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MED

16. Specific lobbying issues

Biodefense Research, Development, and Procurement Issues (Nonfunding)
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---Implementation of Medical Countermeasures Innovation Act
---Tropical Disease Priority Review Voucher (PRV) Program
---S.934/H.R. 2430: FDA Reauthorization Act of 2017

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---Department of Defense Appropriations Act for FY 2018
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018

Funding for Antimicrobial Resistance Programs
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018

Funding for National Institutes of Health
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Medicaid
---Average Manufacturer Price Calculations
---Drug Benefit Design
---Pricing and Rebates

Reimbursement for Innovative Products
---Medicare Part B Physician-Administered Products
---Medicare Part D Prescription Drug Program
---S. 771: Improving Access to Affordable Prescription Drugs
---Third Party Support of Patient Premiums and Cost-Sharing Obligations
---Value-based Contracting and Communications

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB), Natl Economic Council (NEC), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code SMB

16. Specific lobbying issues

Capital Market Enhancements
---Accredited Investor Definition
---Fair Investment Opportunities for Professional Experts Act (House Discussion Draft)
---H.R. 1312/S.416: Small Business Capital Formation Enhancement Act
---H.R. 1343/S.488: Encouraging Employee Ownership Act
---SEC Rule 701
---SEC Small Business Forum

Legislative Amendments to SEC Rule 12b-2 Filing Status Definitions
---H.R. 10: Financial CHOICE Act

Proxy Advisory Services
---Corporate Governance Reform and Transparency Act (House Discussion Draft)
---H.R. 10: Financial CHOICE Act
---Impact of Policies on Small Public Companies

Reform of SEC Regulation D
---Accredited Investor Certification
---H.R. 10: Financial CHOICE Act
---H.R. 79/S. 588: HALOS Act

Sarbanes Oxley Section 404 (b)
---H.R. 10: Financial CHOICE Act
---H.R. 1645: Fostering Innovation Act
---Small Issuer Exemption

Short Selling Transparency

XBRL Exemption for Small Public Companies
---H.R. 10: Financial CHOICE Act
---Small Company Disclosure Simplification Act (House Discussion Draft)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Securities & Exchange Commission (SEC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

Antibiotic & Diagnostic Tax Credit
---H.R. 1840: Reinvigorating Antibiotic and Diagnostic Innovation Act of 2017

Biofuels (Non-Funding)
---Accelerated Depreciation of Biofuels Facilities Extension
---Production Tax Credit Extension

Capital Formation Investment Incentives
---An Act to Modify Net Operating Loss Carryforwards (House Discussion Draft)
---H.R. 2297: PARTNER Act
---Reform of Capital Gains Rules
---Reform of Net Operating Loss Rules
---Reform of Passive Loss Rules

Orphan Drug Issues
---Tax Credit

Renewable Chemicals/Bio-based Products (Non-Funding)
---Investment Tax Credit
---Production Tax Credit
---Expansion of Master Limited Partnerships to Renewable Chemicals
---HR 3149: Renewable Chemicals Act of 2017

Research & Development Tax Credit Reforms
---Refundable R&D Credit

Treatment of Financial Interests as Stock or Indebtedness
---Section 385 Proposed Regulations

Corporate Tax Reform

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Treasury - Dept of

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

Biosimilars
---Brazil Biologics Regulations
---India Biologics Regulations
---Mexico Biologics Regulations

Drug Importation
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---S. 771: Improving Access to Affordable Prescription Drugs
---S.469: Affordable and Safe Prescription Drug Importation Act
---Welch Amendment to: H.R. 2430: FDA Reauthorization Act of 2017
---S.934/H.R. 2430: FDA Reauthorization Act of 2017

Foreign Agricultural Biotechnology Laws and Regulations
---Asynchronous Approvals
---China Biotechnology Regulations
---EU Ag-Biotech Policies and Regulations

Intellectual Property International Enforcement
---Compulsory Licensing
---India

North American Free Trade Agreement (NAFTA) Renegotiation
---Ag-Biotech Provisions
---IP Provisions
---Pricing and Reimbursement Provisions
---Regulatory Harmonization

UN High Level Commission on Access to Medicines
---IP Proposals

World Health Organization (WHO) Cancer Resolution
---Pricing and IP Language

Foreign Drug Data Protection Laws
---Israel

Trade and Foreign Drug Price Controls

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Commerce - Dept of (DOC), Food & Drug Administration (FDA), Natl Security Council (NSC), Natl Economic Council (NEC), U.S. Trade Representative (USTR), Office of Management & Budget (OMB), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization